BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35803261)

  • 1. Human liver organoids for disease modeling of fibrolamellar carcinoma.
    Narayan NJC; Requena D; Lalazar G; Ramos-Espiritu L; Ng D; Levin S; Shebl B; Wang R; Hammond WJ; Saltsman JA; Gehart H; Torbenson MS; Clevers H; LaQuaglia MP; Simon SM
    Stem Cell Reports; 2022 Aug; 17(8):1874-1888. PubMed ID: 35803261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies.
    Nuciforo S; Fofana I; Matter MS; Blumer T; Calabrese D; Boldanova T; Piscuoglio S; Wieland S; Ringnalda F; Schwank G; Terracciano LM; Ng CKY; Heim MH
    Cell Rep; 2018 Jul; 24(5):1363-1376. PubMed ID: 30067989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma.
    El-Derby AM; Khedr MA; Ghoneim NI; Gabr MM; Khater SM; El-Badri N
    J Transl Med; 2024 May; 22(1):487. PubMed ID: 38773585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
    Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
    Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver organoids as a primary human model to study HBV-mediated Hepatocellular carcinoma. A review.
    Sharma S; Rawal P; Kaur S; Puria R
    Exp Cell Res; 2023 Jul; 428(1):113618. PubMed ID: 37142202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
    De Siervi S; Turato C
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
    Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mini-organs with big impact: Organoids in liver cancer studies.
    Khawar MB; Wang Y; Majeed A; Afzal A; Haneef K; Sun H
    Oncol Res; 2023; 31(5):677-688. PubMed ID: 37547759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
    Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organoids as research models for hepatocellular carcinoma.
    Yu JH; Ma S
    Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma.
    Levin SN; Tomasini MD; Knox J; Shirani M; Shebl B; Requena D; Clark J; Heissel S; Alwaseem H; Surjan R; Lahasky R; Molina H; Torbenson MS; Lyons B; Migler RD; Coffino P; Simon SM
    Sci Adv; 2023 Jun; 9(25):eadg7038. PubMed ID: 37343102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surgical therapy of hepatic fibrolamellar carcinoma].
    Meriggi F; Forni E
    Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma.
    Simon SM
    Nat Rev Cancer; 2023 May; 23(5):335-346. PubMed ID: 36932129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
    Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
    Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.
    Yamashita S; Vauthey JN; Kaseb AO; Aloia TA; Conrad C; Hassan MM; Passot G; Raghav KP; Shama MA; Chun YS
    J Gastrointest Surg; 2016 Oct; 20(10):1725-31. PubMed ID: 27456016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A particular hepatocellular carcinoma combining the ordinary and the fibrolamellar variant].
    Zermani R; Charfi L; Kourda N; Farah F; Rammeh S; Trabelsi O; Zaouch A; Ben Jilani S
    Tunis Med; 2005 Jul; 83(7):419-21. PubMed ID: 16220700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
    Sethi S; Tageja N; Singh J; Arabi H; Dave M; Badheka A; Revankar S
    Am J Med Sci; 2009 Dec; 338(6):522-4. PubMed ID: 20010160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
    Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.